AB680 is a potent (5 pM) and selective inhibitor of CD73, a nucleotidase that metabolizes AMP to immunosuppressive extracellular adenosine. AB680 is intended to be used in combination with checkpoint inhibitor biologics in cancer immunotherapy, and has a PK profile for biweekly (Q2W) IV dosing in humans based on a Ph. I study in healthy volunteers.
< 1 minute read
Sep. 18, 2021
AB680: A Potent, Selective, Bi-weekly IV CD73 inhibitor
AB680
potent, selective, Q2W IV CD73 inhibitor completed Ph. I in HV, in dev. for cancer imm. from opt. of known nucleotide CD73 inh. J. Med. Chem., Jul. 20, 2020 Arcus Biosciences, Hayward, CA
Loading...
